Abstract
Mutations in the LRRK2 gene have been implicated in the pathogenesis of Parkinsons disease. This work provides biochemical evidence that the ROC domain of LRRK2 functions as a small GTPase, and the Parkinsons disease-associated mutants do not appear to have reduced GTP hydrolysis activities.
Keywords: LRRK2, ROC domain, small GTPase, GTP binding, Parkinson's disease
Protein & Peptide Letters
Title: The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein
Volume: 16 Issue: 12
Author(s): Qing-Shan Fu, Ai-Xin Song, Su-Xia Li and Hong-Yu Hu
Affiliation:
Keywords: LRRK2, ROC domain, small GTPase, GTP binding, Parkinson's disease
Abstract: Mutations in the LRRK2 gene have been implicated in the pathogenesis of Parkinsons disease. This work provides biochemical evidence that the ROC domain of LRRK2 functions as a small GTPase, and the Parkinsons disease-associated mutants do not appear to have reduced GTP hydrolysis activities.
Export Options
About this article
Cite this article as:
Fu Qing-Shan, Song Ai-Xin, Li Su-Xia and Hu Hong-Yu, The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein, Protein & Peptide Letters 2009; 16 (12) . https://dx.doi.org/10.2174/092986609789839386
DOI https://dx.doi.org/10.2174/092986609789839386 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Acetate Suppresses Lipopolysaccharide-stimulated Nitric Oxide Production in Primary Rat Microglia but not in BV-2 Microglia Cells
Current Molecular Pharmacology Progress in Multiple Sclerosis Genetics
Current Genomics Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design Organotypic Hippocampal Slice Cultures for Studies of Brain Damage, Neuroprotection and Neurorepair
Current Drug Targets - CNS & Neurological Disorders S-Nitrosylation and Attenuation of Excessive Calcium Flux by Pentacycloundecane Derivatives
Medicinal Chemistry Can Transcriptomics Cut the Gordian Knot of Amyotrophic Lateral Sclerosis?
Current Genomics Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Non-Antidepressant Pharmacological Treatment of Obsessive Compulsive Disorder: A Comprehensive Review
Current Clinical Pharmacology Brain Structural Abnormalities at the Onset of Schizophrenia and Bipolar Disorder: A Meta-analysis of Controlled Magnetic Resonance Imaging Studies
Current Pharmaceutical Design Environmental Toxicants as Extrinsic Epigenetic Factors for Parkinsonism: Studies Employing Transgenic C. elegans Model
CNS & Neurological Disorders - Drug Targets A Review of Agents Patented for their Neuroprotective Properties
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Chemokines in Alzheimer's Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Positive Synergism of CPT and MK-801 in Behavioral Tests and in Reduction of Environmental Stress and Redox Signaling Changes in Mice Cerebral Cortex
CNS & Neurological Disorders - Drug Targets